-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2499 Efficacy and Safety of Rivaroxaban Versus Apixaban in Patients with Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational StudiesClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Anticoagulant Drugs, adult, Non-Biological therapies, Clinical Research, thromboembolism, Diseases, Therapies, Adverse Events, Study Population, Human
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Danielle Fredman, MD1,2*, Rotem McNeil, MD1,2*, Ofir Eldar, MD1,2*, Avi Leader, MD2,3*, Anat Gafter-Gvili, MD1,2,3* and Tomer Avni, MD1,2*

1Department of Medicine A, Rabin medical center, Beilinson hospital, Petah Tikva, Israel
2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
3Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Petah Tikva, Israel

Background: Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban are preferred over vitamin K antagonists for the treatment of venous thromboembolism (VTE). We conducted a systematic review and a meta-analysis to compare the efficacy and safety of rivaroxaban versus apixaban in the treatment of VTE.

Methods: We conducted an electronic search for studies that directly compared treatment with rivaroxaban and apixaban in adult patients with VTE. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled using a fixed-effect model unless significant heterogeneity was present (I2 > 40%), then random-effects model was used. The primary efficacy and safety outcomes were recurrent VTE (rVTE) and major bleeding events, respectively.

Results: Nine observational studies were included in our meta-analysis, assessing 24,156 patients for apixaban and 38,847 for rivaroxaban. Pooling of data for our primary efficacy outcome showed a trend towards lower risk of rVTE with apixaban compared to rivaroxaban (RR 0.77, 95% CI 0.57-1.04, I2=53%). Analysis of our primary safety outcome showed a significantly lower risk of major bleeding with apixaban compared to rivaroxaban (RR 0.68, 95% CI 0.61-0.76, I2= 0%). Apixaban was associated with significantly decreased risk of net clinical harm, clinically relevant non major bleeding (CRNMB) and any bleeding, compared to rivaroxaban (RR 0.75, 95% CI 0.61-0.92, I2=50%; RR 0.58, 95% CI 0.50-0.67, I2=7%; RR 0.64, 95% CI 0.59-0.70, I2= 0%, respectively).

Conclusions: Apixaban is associated with a significantly lower risk of major bleeding and significantly decreased net clinical harm, compared to rivaroxaban for treatment of VTE.

Disclosures: Leader: Bayer: Honoraria, Other: honoraria for lectures and scientific advisory boards ; Pfizer: Honoraria, Other: honoraria for lectures and scientific advisory boards ; Sanofi: Honoraria, Other: honoraria for lectures and scientific advisory boards ; Leo-pharma: Honoraria, Other: honoraria for lectures and scientific advisory boards . Gafter-Gvili: Sanofi: Honoraria, Other: honoraria for lectures and advisory board ; Pfizer: Honoraria, Other: honoraria for lectures and advisory board ; Bayer: Honoraria, Other: honoraria for lectures and advisory board ; Medison: Honoraria, Other: honoraria for lectures and advisory board .

*signifies non-member of ASH